Intelligence registry
Public-source dossierfda-warning-letter-d4ba155dabb815bf
Official public recordorganizationRegulatory action

Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC

Authority: www.fda.govCoverage: GlobalPage generated: 2026-08-17
Evidence class
Official public record
Coverage
Global
Record category
Regulatory action
Page generated
2026-08-17
Linked public records

No verified ownership, offshore or transport links have been attached to this record yet.

Source and status notice
The relationship or event is sourced to a government or intergovernmental publication. Always verify the live source record and identifiers before relying on this page.

Compliance Profile

"Public-record notice: Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC appears in official public record data. The record is informational and should be checked against the original publisher before legal, financial or counterparty decisions are made."

Banking Impact

This public record does not establish a banking prohibition. Any onboarding or transaction decision should use the original source, a verified identity match and the institution's applicable legal framework.

Legal Status

This is an informational public record, not a sanctions, exclusion or enforcement conclusion unless the page expressly identifies an official issuing authority and record.

Public source metadata

Source: FDA Warning Letters
Full Legal NameNephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC
Known aliasesOffice of Pharmaceutical Quality Operations, Division II / Compounding Pharmacy/Adulterated Drug Products
Source datasets
FDA WARNING LETTERfda_warning_letters
Record statusInformational public record
Publishing authoritywww.fda.gov
Identifiers2022-10-21 / Compounding Pharmacy/Adulterated Drug Products
Record timelineFirst seen: 2022-10-21Last seen: 2022-10-21
Risk Topicsreg.action, reg.warn, sector.medical
Original sourceView source record

Compliance Context Review

Independent assessment

SIC Group prepares source-backed risk context, exposure memos, and remediation pathways for entities seeking to clarify a public record or counterparty signal.

Source-list verification
Banking and counterparty exposure memo
Regulatory status and remediation triage
Request Risk Assessment
Confidential Review
Report an error or request a correction
Export PDFSubscriber Only